| |
Unleash the Full Potential of Your Data! Our BioELN Solution maximizes your success with efficient resources and knowledge management. Transform data into discoveries with Signals Notebook. Learn more in our white paper.
|
|
Today's Big NewsMay 11, 2023 |
|
Wednesday, May 17, 2023 2:00pm ET / 11:00am PT Join this webinar to learn more about the opprtunity medical affairs teams and medical science liaisons (MSLs) have to engage with HCPs in clinical discussions and bridge care gaps by providing crucial insights into evidence-based medicine. Register now to learn more.
|
|
| By Nick Paul Taylor Innovent Biologics has strengthened its pitch for the Chinese obesity market with fresh phase 2 data. The update shows giving mazdutide, a molecule from Eli Lilly’s deep bench of obesity assets, at a higher dose dialed up the placebo-adjusted weight loss to 15.4% after 24 weeks. |
|
|
|
By Angus Liu Mirati Therapeutics' new KRAS cancer drug Krazati surprised analysts in its first full quarter on the market. But investors remain more interested in the company's plan for newly diagnosed lung cancer patients. |
By Andrea Park After watching Philips’ valuation plummet more than 60% since the onset of the June 2021 recall of millions of its respiratory devices, shareholders aren’t letting the losses slide. |
By Zoey Becker Otsuka and Lundbeck's atypical antipsychotic Rexulti is now the first drug in the U.S. to treat Alzheimer's disease related agitation. This new use follows prior approvals in schizophrenia and major depressive disorder. |
|
Tuesday, May 23, 2023 | 2pm ET / 11am PT Clinical trials are complex, time-consuming, and costly. But what if you could use simulation to guide your decisions and optimize your trial design? In this webinar, we'll discuss the power of simulation-guided trial design (SGTD) and explain its benefits to clinical development strategies. Register now to join us.
|
|
By Gabrielle Masson NYBC Ventures has unveiled as one of the first venture funds to focus solely on advancing new blood and cell-based therapies, with $50 million in hand from the New York Blood Center. |
By Angus Liu Fierce Pharma is asking you, the dedicated employees working in the biopharma industry, to tell your stories of the pandemic—in photographs. |
By Nick Paul Taylor BioNTech has swiftly rejected an oral mRNA delivery technology. Barely one year after signing up to work with Matinas BioPharma, BioNTech found an initial mouse study failed to show preclinical activity—leading it to join Gilead on the list of companies to dump the biotech in recent months. |
By Zoey Becker Even after top diabetes players Eli Lilly, Novo Nordisk and Sanofi slashed their insulin prices earlier this year, the companies still aren't off the hook. The CEOs of the companies—along with three PBM execs—faced intense questioning at a Bernie Sanders-led Senate committee hearing on insulin affordability. |
By James Waldron Takeda may have caught attention recently for ending work on its early-stage gene therapy R&D, but a close reading of the Japanese pharma’s latest earnings report reveals it has also culled a couple of gastrointestinal assets. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we discuss the rise of digital therapeutics and remaining barriers to implementation. We also talk about what it takes to fix the PBM industry. |
|
|---|
|
|
|
Thursday, May 25, 2023 | 10:00am ET / 7:00am PT Join the webinar and discover our MVA technology platform and explore the advantages for development and manufacturing of multiple vaccines and cell and gene therapeutics. Register now.
|
|
| WhitepaperChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookDiscover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
| ResearchWhat role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| WhitepaperThis paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperPreparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
